NUTLEY, N.J.--(BUSINESS WIRE)--In a powerful demonstration of its commitment to continued growth and employee well-being, global pharmaceutical company Eisai has announced its selection of SJP Project Solutions to lead a world-class team in the build-out of its new U.S. headquarters at ON3, a high-tech bio-ecosystem in Nutley, New Jersey.
Eisai, an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., will be relocating its U.S. headquarters from Woodcliff Lake to the entirety of 200 Metro Boulevard at ON3, in Q4 of 2021. Eisai signed a lease in August for 300,000 square feet at the campus and has tapped SJP Project Solutions -- the third-party development management division of SJP Properties -- to work with its in-house team. As part of the process, the SJP team will collaborate with ON3 owner Prism Capital Partners on the base-building improvements, and will work closely with leading global architecture firms HLW and AMA on the design and build-out of Eisai’s new headquarters, where the company will be transferring up to 1,200 corporate staff and research and development functions.
“Continued and constant growth of the healthcare ecosystem is essential during these challenging times,” said Joel Beetsch, PhD, Vice President of Corporate Affairs at Eisai Inc. “The combination of healthcare innovation and the knowledge-creating space in which it takes place is a critical and powerful partnership. Eisai deeply appreciates the expertise of SJP to help drive the delivery of healthcare solutions to patients and their families.”
Eisai conducted a meticulous search for a headquarters project team that will effectively support its commitment to “human health care” — Eisai’s corporate philosophy denoting the key role that patients, their families and consumers all play in the healthcare industry. Eisai employees embody this philosophy daily as part of a mission-driven culture that is guiding the company’s workplace strategy, with a design that prioritizes safety, collaboration and innovation.
“As a company that is on the leading edge of the life sciences sector, Eisai was discerning and deliberate in its process for assembling a team to deliver a purpose-built headquarters that will be additive to its operations and facilitate employees’ invaluable work,” said Peter Bronsnick, President — New Jersey Region at SJP Properties. “Now, more than ever, making real estate decisions with your workforce’s well-being in mind is crucial for business continuity, and Eisai is the perfect example of a company that is leading from the front in this regard.”
SJP’s Project Solutions division has years of experience not just delivering superior, complex construction projects, but also specifically in creating resilient, ideal headquarters locations for international companies across the New York Metro area. Since its launch in 2018, the division has grown to include assignments totaling over three million square feet of build-out and ground-up construction projects. Notable projects include: the repositioning of Mack-Cali’s Harborside mixed-use development along the waterfront in Jersey City, N.J.; the build-out of EY’s offices in Hoboken, N.J.; the build-out of SIR Capital Management’s offices at 11 Times Square in Manhattan; the development of Prudential Financial’s headquarters in Newark, N.J.; and the development of Life Time Work’s office in Iselin, N.J.
To learn more about SJP Project Solutions and its third-party management offerings, visit www.sjpprojectsolutions.com.
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at https://us.eisai.com and follow us on Twitter and LinkedIn.
About SJP Properties
Headquartered in New York City, SJP Properties is a vertically integrated commercial and residential real estate owner, developer, investor, asset manager, construction manager and property manager. The expertise of the company’s core in-house team of professionals encompasses the entire development process, from site selection through coordination of tenant move-in for large multi-phase projects, including numerous Class A build-to-suit developments and individual tenant build-outs. Well known for the creation of unparalleled lifestyle-focused developments, SJP is committed to meticulous design and engineering development plans that reflect a keen understanding of market demand.
Having sustained an unblemished track record of success, SJP has established relationships with many of the industry’s leading investors and financial institutions, providing unparalleled access to capital. visit www.sjpproperties.com or follow us on LinkedIn and Instagram.
